What Nextech Invest does

Nextech Invest is a venture capital and private equity firm headquartered in Zurich, Switzerland, with additional offices in Boston and San Francisco. The firm specializes exclusively in precision oncology, investing across early, mid-, late-stage, and emerging-growth biotechnology companies developing transformative cancer medicines. Nextech's stated core offering is hands-on venture capital financing and strategic support through critical moments of scientific and clinical validation, from pre-clinical to clinical proof-of-concept. Portfolio activity spans a broad range of modalities including ADCs (Tubulis), RNA editing (AIRNA), macrocycles (Circle Pharma), allosteric small molecules (Atavistik Bio), precision oncology discovery platforms (Stipple Bio), and targeted therapies (ORIC Pharmaceuticals, Revolution Medicines), with the firm reporting 60+ portfolio companies. Recent rounds show significant co-lead and lead positions in financings of $100M–$305M, alongside expansion into public markets under a dedicated Public Markets effort. There is a noted discrepancy between firmographic founding year (1998) and the company-history milestone anchoring the current oncology-focused mandate to Thilo Schroeder's arrival in 2012.

Nextech generates revenue through the standard venture capital model: management fees on funds under management and carried interest (performance fees) from successful portfolio exits and realizations. Pricing, AUM, and revenue are not publicly disclosed. The firm sells financial and strategic support to a single customer segment — emerging precision oncology biotechnology companies — sourced primarily through its scientific advisory network, board relationships, and reputation. There are no software products, technology platforms, AI/ML capabilities, or subscription services in the offering; value delivery is investor capital combined with scientific expertise and board-level governance. Go-to-market is sales-led, with deal flow driven by referrals and direct network from scientific partners at institutions including Dana-Farber, Harvard, and ETH Zurich.

The firm is privately held, with no parent company or public ticker. It operates through a Swiss parent entity (Nextech Invest AG) and a US LLC (Nextech Ventures (US) LLC). Leadership comprises three Managing Partners (Thilo Schroeder, Rocco Sgobbo, Kanishka Pothula), a Chairman (Alexis Borisy, founding investor of Foundation Medicine, Blueprint Medicines, Relay Therapeutics, Tango Therapeutics, and Revolution Medicines), additional partners and principals, and a board that includes senior figures from J.P. Morgan and Partners Group/Schroder Adveq.

Name

Nextech Invest

Legal name

Nextech Invest AG

Website

https://nextechinvest.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Nextech Invest is a Zurich-based venture capital firm that invests exclusively in precision oncology biotechnology companies across modalities and stages. The firm provides venture financing, board leadership, and scientific support to a portfolio of 60+ oncology biotechs from offices in Zurich, Boston, and San Francisco.

Ownership category

akta.pro rank

Product category

Venture Capital and Private Equity (Life Sciences/Oncology)

NAICS

Portfolio Management and Investment Advice (523940), Management Consulting Services (54161)

SIC

Investment Advice (6282), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industries

Healthcare & Life Sciences Growth Equity (FSANACAB), Oncology Specialty Pharmaceuticals (HLAIACAA), Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)

Keywords

• Venture capital investing
• Oncology biotechnology funding
• Precision medicine investment
• Life sciences private equity
• Biotech venture capital

Headquarters

HQ city

Zürich

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Management Fees and Carried Interest: As a venture capital firm, Nextech Invest generates revenue through management fees charged on funds under management and carried interest (performance fees) from successful portfolio company exits and realizations.

Go-to-market motion1 record

Marketing channels1 record

Core offering

Nextech Invest is a Zurich-based venture capital firm that provides equity financing and hands-on strategic support to emerging biotechnology companies developing transformative precision oncology medicines. The firm identifies first and best-in-class targeted therapies regardless of drug modality and nurtures portfolio companies through critical moments of scientific validation and value creation, from pre-clinical to clinical proof-of-concept stages. The firm manages a portfolio of more than 60 oncology-focused biotech companies and supports them through board leadership, scientific due diligence, and follow-on capital deployment.

Product overview

Nextech Invest is a venture capital firm based in Zurich, Switzerland, focused exclusively on investing in precision oncology biotechnology companies. The firm does not offer a unified software product or platform but rather provides venture capital financing, hands-on board leadership, and strategic support to its portfolio companies. The core offering consists of investment services that fuel the success of emerging biotech companies by identifying transformative cancer medicines and nurturing them through critical moments of scientific validation and value creation. The firm leverages deep scientific knowledge combined with investment expertise to support companies across the development pipeline from pre-clinical to clinical proof-of-concept stages.

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Capital Investment Services Equity financing in venture and growth rounds (Series A through F) for emerging precision oncology biotechnology companies, supporting transformative cancer medicines through clinical validation and value creation milestones.
• Portfolio Company Strategic Support Hands-on board leadership, scientific due diligence, and ongoing strategic guidance to portfolio companies across the development pipeline from pre-clinical to clinical proof-of-concept stages.
• Public Markets Investment Public equity investments in oncology biotechnology companies, including significant positions in publicly traded companies such as Revolution Medicines (NASDAQ: RVMD).

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• 5AM Ventures: 5AM Ventures is a science-focused venture firm investing in early-stage life sciences companies, with comparable portfolio construction across therapeutics platforms and similar AUM scale to Nextech. Both firms concentrate on founder-led biotech around inflection points.
• Third Rock Ventures: Third Rock Ventures is a biotech-focused venture firm that launches and builds companies around breakthrough science, with deep ties to Nextech via Chairman Alexis Borisy (former Third Rock Partner). Operates with comparable scientific validation model and oncology focus.
• RA Capital Management: RA Capital is a crossover-focused biotech investment firm that participates across private and public markets, co-leading rounds alongside Nextech (Stipple Bio, Parabilis Medicines). Comparable in its specialist biotech focus and public/private investment approach.
• Versant Ventures: Versant Ventures is a healthcare-focused venture firm with significant presence in both US and European biotech markets and a comparable strategy of building companies around precision medicine platforms. The firm runs a similar blend of early-stage venture and company creation.
• Medicxi: Medicxi is a European-headquartered biotech-focused venture firm with offices in London and Geneva, operating a comparable model of scientific diligence and portfolio construction in precision medicine. Geographic overlap with Nextech in continental Europe.
• Atlas Venture: Atlas Venture is a specialist biotech-focused venture firm that builds companies from inception, with deep scientific expertise and a hands-on company-creation model closely mirroring Nextech's oncology-specialist approach. Both firms target early-stage biotech founders and operate with relatively lean teams.
• venBio: venBio is a venture firm exclusively focused on biotechnology and biopharmaceutical investments, with a comparable specialist focus and similar check sizes. Both firms concentrate on therapeutic platforms with strong scientific underpinnings.

Regional players

• Forbion: Forbion is a leading European life sciences venture capital firm based in the Netherlands, with comparable precision medicine focus and co-investment activity with Nextech portfolio companies. Direct comparable in European biotech venture but regionally anchored differently.

Broad incumbents

• OrbiMed: OrbiMed is one of the largest healthcare-dedicated investment firms globally, covering venture, growth, public, and credit across therapeutics and medical devices. Larger and broader than Nextech but operates in overlapping precision medicine venture stage.
• ARCH Venture Partners: ARCH Venture Partners is a large, established biotech and technology venture firm that has co-invested alongside Nextech (e.g., Be Biopharma). Operates at significantly larger AUM scale and broader mandate, but directly comparable in early-stage biotech investing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/nextechinvest
• LinkedInlinkedin.com/company/nextech-invest-ltd.

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments105 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nextech Invest